2019 Year 12 Month 13 On [date], Nilotinib monoclonal antibody combined with concurrent chemoradiotherapy for the treatment of newly diagnosed children with diffuse intrinsic pontine glioma was hosted by BIOTECH PHARMACEUTICAL CO., LTD. DIPG The investigator meeting for the multi-center, prospective, single-arm clinical study project was successfully held in Beijing.

This project is jointly led by Professor Jiang Mawei from Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, and Professor Qiu Xiaoguang from Beijing Tiantan Hospital, Affiliated to Capital Medical University. Leading pediatric neuro-oncology clinicians in China—including Professor Ma Wenbin from Peking Union Medical College Hospital, Professor Xu Jiankun from Xuanwu Hospital of Capital Medical University, Professor Tao Rongjie from Shandong Provincial Cancer Hospital, and Professor Wang Gang from Zhengzhou Cancer Hospital—along with Dr. Miao Jia, Director of Huaxi Hospital at Sichuan University (representing the clinical trial institution), also attended the investigator meeting. Notably, all of these hospitals are participating institutions in this ongoing clinical research project.

Childhood Diffuse Intrinsic Pontine Glioma Diffuse intrinsic pontine glioma ， DIPG ) is a rare malignant brainstem tumor, primarily affecting the following population: 5-9 Children of this age have a median survival period of just 9-12 Months, 2 Annual survival rate is only 10% to 25% Clinically, the prognosis is extremely poor, and effective treatment options remain scarce. Therefore, there is an urgent need to identify and explore new therapeutic approaches and medications.

At the meeting, experts thoroughly discussed nimotuzumab treatment for children. DIPD The clinical trial protocol addressed key issues such as inclusion and exclusion criteria, the study treatment plan, timing of imaging assessments, dosing characteristics for pediatric participants, and safeguards to protect the rights of child subjects—and consensus was reached on these critical aspects. Professor Jiang Mawei stated that children DIPG With a low incidence rate but high mortality, and currently no effective treatment options available, clinical trial results of nivolumab combined with radiotherapy and chemotherapy may provide new hope. DIPG The young patient brings new hope. Professor Qiu Xiaoguang has dedicated years to researching the treatment of nervous system tumors, and he calls on everyone to join forces in striving to successfully complete clinical trials with high quality.

Biotech Pharma is committed to delivering safe and effective targeted therapies to cancer patients in China, with a strong focus on clinical research and development in the field of treating rare pediatric tumors. The company will actively support the ongoing trials, ensuring robust support for clinical studies.

Nimotuzumab is a recombinant humanized monoclonal antibody jointly developed by BIOTECH PHARMACEUTICAL CO., LTD and Cuba. EGFR Monoclonal antibody—this drug has been approved by the United States FDA And the European Union EMA Dual certification, approved as an orphan drug for advanced glioma, and already available in overseas markets such as Cuba. 11 A national clinical application for the treatment of gliomas. We hope this study, conducted domestically, will explore the combination of nimotuzumab with radiotherapy and chemotherapy. DIPG The clinical study results can provide DIPG The pediatric patient brings new treatment options, helping to address the shortage of medicines for children with cancer in China. Difficult Question.